Servier has secured global rights to develop and commercialize BDTX-4933, a Phase 1 targeted therapy designed to address both RAS mutations and RAF alterations in solid tumors, particularly non-small cell lung cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.